Rznomics, Inc. announced to secure its expanded access program (EAP) from the United States Food and Drug Administration (FDA) for RZ-001, ...

RNA therapeutics promise rapid, personalized and flexible treatments against multiple diseases. In this article, we will ...

Chronic obstructive pulmonary disease (COPD) affects nearly 12 million people in the U.S. alone and is the third leading ...

The collaboration aims to identify a small molecule that targets mutant androgen receptor (AR) mRNA splicing and causes selective destruction of the disease-causing mRNA. By modulating mRNA splicing, ...

Ractigen's RAG-21, a treatment for ALS linked to mutations in the FUS gene, has been granted orphan drug designation in the U ...

Immune checkpoint blockade (ICB) therapies can be very effective against some cancers by helping the immune system recognize ...

The presumptive new CDC director, Dave Weldon, is a known vaccine safety skeptic. In contrast, the FDA choice — Johns Hopkins ...

Explore the challenges and advancements in anti-EGFR antibody treatment for metastatic colorectal cancer. Discover how ...

Shanghai Ark Biopharmaceutical (ArkBio) has concluded enrolment and dosing for a Phase I trial of fully human monoclonal ...

Discover a recent clinical trial that explored the efficacy of combining pembrolizumab, an anti-PD-1 immunotherapy, with ...

Fintel reports that on November 25, 2024, HC Wainwright & Co. initiated coverage of Sarepta Therapeutics (NasdaqGS:SRPT) with ...

Gene Synthesis Market. The global gene synthesis market is poised for extraordinary expansion, with its valuation projected ...